These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11521772)

  • 81. Inferring speaker attributes in adductor spasmodic dysphonia: ratings from unfamiliar listeners.
    Isetti D; Xuereb L; Eadie TL
    Am J Speech Lang Pathol; 2014 May; 23(2):134-45. PubMed ID: 24686338
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Teaching video NeuroImage: Spasmodic dysphonia: adductor and abductor.
    Reich SG; Meyer T
    Neurology; 2008 May; 70(19):e78. PubMed ID: 18458222
    [No Abstract]   [Full Text] [Related]  

  • 83. Liquid-type Botulinum Toxin Type A in Adductor Spasmodic Dysphonia: A Prospective Pilot Study.
    Cha W; Jang JY; Wang SG; Kang JH; Jo MG
    J Voice; 2017 May; 31(3):378.e19-378.e24. PubMed ID: 27520509
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Treatment of adductor-type spasmodic dysphonia by surgical myectomy: a preliminary report.
    Koufman JA; Rees CJ; Halum SL; Blalock D
    Ann Otol Rhinol Laryngol; 2006 Feb; 115(2):97-102. PubMed ID: 16514790
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Long-term voice handicap index after type II thyroplasty using titanium bridges for adductor spasmodic dysphonia.
    Sanuki T; Yumoto E; Kodama N; Minoda R; Kumai Y
    Auris Nasus Larynx; 2014 Jun; 41(3):285-9. PubMed ID: 24369905
    [TBL] [Abstract][Full Text] [Related]  

  • 86. A comparison of the VHI, VHI-10, and V-RQOL for measuring the effect of botox therapy in adductor spasmodic dysphonia.
    Morzaria S; Damrose EJ
    J Voice; 2012 May; 26(3):378-80. PubMed ID: 20951552
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Spectral amplitude measures of adductor spasmodic dysphonic speech.
    Cannito MP; Buder EH; Chorna LB
    J Voice; 2005 Sep; 19(3):391-410. PubMed ID: 16102666
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Unilateral versus bilateral botulinum toxin injections in spasmodic dysphonia: acoustic and perceptual results.
    Adams SG; Hunt EJ; Charles DA; Lang AE
    J Otolaryngol; 1993 Jun; 22(3):171-5. PubMed ID: 8371328
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Judgment of voice improvement after recurrent laryngeal nerve section for spastic dysphonia: clinicians versus patients.
    Sapir S; Aronson AE; Thomas JE
    Ann Otol Rhinol Laryngol; 1986; 95(2 Pt 1):137-41. PubMed ID: 3516048
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Effects of botulinum toxin on pathophysiology in spasmodic dysphonia.
    Bielamowicz S; Ludlow CL
    Ann Otol Rhinol Laryngol; 2000 Feb; 109(2):194-203. PubMed ID: 10685573
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [Abnormal adductor movement of the vocal cords in spasmodic dysphonia].
    Shibusawa M
    Nihon Jibiinkoka Gakkai Kaiho; 1993 Apr; 96(4):659-64. PubMed ID: 8509938
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Evaluation of voice quality in adductor spasmodic dysphonia before and after botulinum toxin treatment.
    Langeveld TP; van Rossum M; Houtman EH; Zwinderman AH; Briaire JJ; Baatenburg de Jong RJ
    Ann Otol Rhinol Laryngol; 2001 Jul; 110(7 Pt 1):627-34. PubMed ID: 11465821
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Partial thyroarytenoid myectomy: an animal study investigating a proposed new treatment for adductor spasmodic dysphonia.
    Genack SH; Woo P; Colton RH; Goyette D
    Otolaryngol Head Neck Surg; 1993 Mar; 108(3):256-64. PubMed ID: 8464639
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Differential diagnosis of muscle tension dysphonia and adductor spasmodic dysphonia using spectral moments of the long-term average spectrum.
    Houtz DR; Roy N; Merrill RM; Smith ME
    Laryngoscope; 2010 Apr; 120(4):749-57. PubMed ID: 20222024
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Female predominance in spasmodic dysphonia.
    Adler CH; Edwards BW; Bansberg SF
    J Neurol Neurosurg Psychiatry; 1997 Nov; 63(5):688. PubMed ID: 9408119
    [No Abstract]   [Full Text] [Related]  

  • 96. Assessing the effectiveness of botulinum toxin injections for adductor spasmodic dysphonia: clinician and patient perception.
    Braden MN; Johns MM; Klein AM; Delgaudio JM; Gilman M; Hapner ER
    J Voice; 2010 Mar; 24(2):242-9. PubMed ID: 19481417
    [TBL] [Abstract][Full Text] [Related]  

  • 97. [Treatment of spasmodic dysphonia with botulinum toxin].
    Klap P; Marion MH; Perrin A; Fresnel-Elbaz E
    Ann Otolaryngol Chir Cervicofac; 1991; 108(8):477-82; discussion 482-3. PubMed ID: 1789624
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Abnormal soft palate posturing in patients with laryngeal movement disorders.
    Lundy DS; Casiano RR; Lu FL; Xue JW
    J Voice; 1996 Dec; 10(4):348-53. PubMed ID: 8943138
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Aerodynamic assessment of phonatory onset in Parkinson's disease: evidence of decreased scaling of laryngeal and respiratory control.
    Hammer MJ
    J Parkinsons Dis; 2013; 3(2):173-9. PubMed ID: 23750188
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Long term phonatory function following acoustic neuroma surgery: a cohort study.
    Abbas-Kayano RT; Solla D; Rabelo NN; Gomes M; Cabrera H; Teixeira MJ; Figueiredo EG
    Acta Otolaryngol; 2020 Aug; 140(8):646-650. PubMed ID: 32347145
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.